olivLaw · US equity research
ASP Isotopes Inc. ASPI
Miscellaneous Chemical Products · SIC 2890 · Vertical: Miscellaneous Chemical Products (SIC 2890)
ASP Isotopes is an advanced materials company building a proprietary isotope enrichment platform for nuclear medicine, semiconductors and nuclear energy. It recently expanded through the Renergen acquisition, a South African producer of liquid helium and LNG, while its 2025 net loss of 159.8 million USD shows that its projects are still in an investment phase.
At the close of 04 Nov 2026, ASP Isotopes Inc. (ASPI) stock was 1.91 USD (+5.52% on the day), with market capitalisation 292.8 m USD, dividend yield 0.00%, beta 2.72, 52-week range 1.81–9.00 USD. Latest reported quarter (Q2 2026): revenue of 5.1 m USD (+327.6% YoY), net income of -34.0 m USD, diluted EPS -0.27 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 34.4
- weak (30–45)
- Bollinger (20, 2)
- 1.66 – 2.62
- in the lower half of the band · %B 0.26 · band width 45.1%
- SMA 50 / 200
- 2.85 / 4.78
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.27 / -0.29
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −34.8% | −1.1% | −33.7 pp | — |
| 3 months | −52.8% | −0.5% | −52.4 pp | — |
| 6 months | −65.5% | +4.4% | −69.9 pp | — |
| Year to date | −64.3% | +12.3% | −76.6 pp | — |
| 1 year | −76.8% | +13.5% | −90.3 pp | +19.0% |
| 3 years | +81.9% | +76.4% | +5.5 pp | −1.1% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1 m | 1.2 m | 1.1 m | 1.2 m | 4.9 m | 16.7 m | 4.2 m | 5.1 m |
| Cost of revenue | 793.7 k | 588.5 k | 775.0 k | 626.0 k | 4.5 m | 14.6 m | 2.5 m | 3.6 m |
| Gross profit | 294.0 k | 605.1 k | 327.0 k | 572.0 k | 423.2 k | 2.1 m | 1.7 m | 1.5 m |
| Research & development | 1.0 m | 1.4 m | 1.5 m | 880.0 k | 3.1 m | 6.8 m | 5.3 m | 6.8 m |
| Operating income | -5.4 m | -7.6 m | -8.0 m | -12.0 m | -15.0 m | -25.0 m | -24.9 m | -34.2 m |
| Depreciation & amortisation | — | 45.4 k | 149.0 k | 530.0 k ≈ | 296.3 k ≈ | 936.7 k | 3.1 m | 1.2 m ≈ |
| Interest expense | 91.0 k | 85.2 k | 87.0 k | 82.0 k | 146.1 k | 260.0 k | 1.7 m | 1.8 m |
| Pre-tax income | -7.4 m | -9.1 m | -8.5 m | -75.1 m | -12.8 m | -63.1 m | -26.7 m | -34.1 m |
| Income tax | -8.4 k | 153.2 k | -71.0 k | 95.0 k | 73.6 k | 183.9 k | -31.0 k | -97.0 k |
| Net income | -7.4 m | -9.2 m | -8.5 m | -75.2 m | -12.9 m | -63.3 m | -7.1 m | -34.0 m |
| Diluted EPS | -0.12 | -0.14 ≈ | -0.12 | -1.03 | -0.15 | -0.61 ≈ | -0.06 | -0.27 |
| Operating cash flow | -4.8 m ≈ | -3.8 m | -3.2 m | -7.9 m ≈ | -8.9 m ≈ | -17.9 m | -17.8 m | -23.3 m ≈ |
| Capex | 4.5 m ≈ | 1.3 m | 2.3 m | 1.8 m ≈ | 3.1 m ≈ | 2.4 m | 6.1 m | 4.1 m ≈ |
| Dividends paid | 0 ≈ | 341 | — | — | 0 ≈ | 0 | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | ⚠ 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 433.0 k | 4.1 m | 23.8 m |
| Revenue YoY | unavailable | unavailable | — | +475.5% |
| Net income | -4.9 m | -16.3 m | -32.4 m | -159.8 m |
| Net income YoY | unavailable | unavailable | — | unavailable |
| Diluted EPS | -0.18 | -0.49 | -0.63 | -2.11 |
| Diluted EPS YoY | unavailable | unavailable | — | unavailable |
| net % | unavailable | -3,762.9% | -782.4% | -670.2% |
| Free cash flow | -7.4 m | -7.7 m | -26.4 m | -47.4 m |
The series breaks before 2024: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 279.6 m USD
- Financial debt
- 2.1 m USD
- Net debt
- -277.5 m USD
- Equity
- 262.9 m USD
- Total assets
- 498.0 m USD
- Debt / equity
- 0.01x
- Current ratio
- 12.23x
- ROE
- -101.8%
- ROA
- -54.0%
- FCF margin
- -198.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 0 | 433.0 k | 4.1 m | 23.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Cost of revenue | 0 | 294.1 k | 2.5 m | 20.4 m | SEC (XBRL)· 10 Apr 2026verified |
| Gross profit | 0 | 139.0 k | 1.6 m | 3.4 m | SEC (XBRL)· 10 Apr 2026verified |
| Research & development | 1.3 m | 764.6 k | 3.1 m | 12.4 m | SEC (XBRL)· 10 Apr 2026verified |
| Operating income | -5.1 m | -16.0 m | -26.4 m | -59.9 m | SEC (XBRL)· 10 Apr 2026verified |
| Depreciation & amortisation | — | — | 471.0 k | 1.9 m | SEC (XBRL)· 10 Apr 2026verified |
| EBITDA | — | — | -25.9 m ≈ | -58.0 m ≈ | SEC (XBRL)· 10 Apr 2026derived |
| Interest expense | 0 | 118.5 k | 259.0 k | 575.0 k | SEC (XBRL)· 10 Apr 2026verified |
| Pre-tax income | -4.9 m | -16.3 m | -32.3 m | -159.6 m | SEC (XBRL)· 10 Apr 2026verified |
| Income tax | 0 | -6.1 k | 111.0 k | 282.0 k | SEC (XBRL)· 10 Apr 2026verified |
| Net income | -4.9 m | -16.3 m | -32.4 m | -159.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Diluted EPS | -0.18 | -0.49 | -0.63 | -2.11 | SEC (XBRL)· 10 Apr 2026verified |
| Weighted average diluted shares | — | 33.1 m | 55.7 m | 83.0 m | SEC (XBRL)· 10 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 2.4 m | 7.9 m | 61.9 m | 279.6 m | SEC (XBRL)· 20 May 2026verified |
| Receivables | 0 | 216.5 k | — | — | SEC (XBRL)· 15 May 2024verified |
| Inventories | — | 0 | 66.0 k | 1.1 m | SEC (XBRL)· 10 Apr 2026verified |
| Current assets | 3.3 m | 10.5 m | 65.7 m | 399.9 m | SEC (XBRL)· 10 Apr 2026verified |
| Property, plant & equipment, net | 8.2 m | 10.7 m | 22.4 m | 33.3 m | SEC (XBRL)· 20 May 2026verified |
| Goodwill | 0 | 3.3 m | 3.2 m | 5.2 m | SEC (XBRL)· 20 May 2026verified |
| Intangibles (excl. goodwill) | — | — | — | 675.0 k | SEC (XBRL)· 20 May 2026verified |
| Total assets | 12.5 m | 27.5 m | 94.3 m | 498.0 m | SEC (XBRL)· 10 Apr 2026verified |
| Accounts payable | 1.4 m | 1.1 m | 1.0 m | 3.8 m | SEC (XBRL)· 20 May 2026verified |
| Short-term debt | — | — | 939.0 k | 584.0 k | SEC (XBRL)· 20 May 2026verified |
| Long-term debt | — | — | 1.4 m | 1.5 m | SEC (XBRL)· 10 Apr 2026verified |
| Current liabilities | 1.9 m | 5.7 m | 7.1 m | 32.7 m | SEC (XBRL)· 10 Apr 2026verified |
| Total liabilities | 2.7 m | 8.7 m | 43.2 m | 235.1 m | SEC (XBRL)· 10 Apr 2026verified |
| Equity | 9.8 m | 18.8 m | 51.2 m | 262.9 m | SEC (XBRL)· 10 Apr 2026verified |
| Shares outstanding at year end | 34.4 m | — | — | — | SEC (XBRL)· 22 Dec 2022verified |
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | -2.9 m | -5.4 m | -16.7 m | -37.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Capex | 4.5 m | 2.3 m | 9.7 m | 9.7 m | SEC (XBRL)· 10 Apr 2026verified |
| Free cash flow | -7.4 m ≈ | -7.7 m ≈ | -26.4 m ≈ | -47.4 m ≈ | SEC (XBRL)· 10 Apr 2026derived |
| Investing cash flow | -4.5 m | -2.5 m | -11.4 m | -110.8 m | SEC (XBRL)· 10 Apr 2026verified |
| Financing cash flow | 6.6 m | 13.4 m | 82.5 m | 371.6 m | SEC (XBRL)· 10 Apr 2026verified |
| Dividends paid | — | 0 | 2.8 m | 0 | SEC (XBRL)· 10 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- score weight coverage: 41.7% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 292.8 m USD
Key indicators
Coverage and freshness
Score by group
42% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 41.7% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -72.4% | 0 (vs peers) | 25% |
| Net margin · Quality | -380.3% | 0 (vs peers) | 15% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -25.3x | 0 (on a fixed band) | 15% |
| Current ratio · Balance sheet | 3.9x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -28.5% | 0 (on a fixed band) | 20% |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 15% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality0/100 · 2/3 factors with a value
- Returns· partial0/100 · 1/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ASP Isotopes Inc. (ASPI). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 23.8 m USD in 2025; YoY growth 475.5%; net margin -380.3%; ROE -80.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 41.7% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 3.9x
What contradicts it
- ROIC: -72.4%
- Net margin: -380.3%
- Interest coverage: -25.3x
- FCF yield: -28.5%
- Shareholder yield (distributions): 0.0%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Miscellaneous Chemical Products (SIC 2890) · same industry (4-digit SIC) · compared with 7 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ESIElement Solutions Inc | 8.1 bn | 39.6 | 7.4% | 5.9% | +3.8% | +29% / +60% |
| CBTCabot Corp | 3.9 bn | 21.1 | 12.1% | 5.2% | −7.0% | +20% / −1% |
| WDFCWd-40 Company | 3.1 bn | 38.3 | 30.4% | 12.0% | +11.0% | +19% / −4% |
| FTKFlotek Industries Inc | 895.4 m | 25.0 | 37.8% | 13.0% | +26.9% | +73% / +685% |
| OECOrion S.A. | 331.8 m | — | -8.1% | -1.8% | −3.8% | +16% / −75% |
| ASPIASP Isotopes Inc. | 292.8 m | — | -80.9% | -380.3% | +475.5% | −77% / +82% |
| ARQArq, Inc. | 81.8 m | — | -25.0% | -38.5% | +10.4% | −50% / −31% |
| FSIFlexible Solutions International, Inc | 80.1 m | — | -8.2% | -8.8% | +0.7% | −8% / +313% |
1- and 3-year price returns: for ASPI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
ASP Isotopes is an advanced materials company building a proprietary isotope enrichment platform for nuclear medicine, semiconductors and nuclear energy. It recently expanded through the Renergen acquisition, a South African producer of liquid helium and LNG, while its 2025 net loss of 159.8 million USD shows that its projects are still in an investment phase.
SWOT
Strengths
- A proprietary enrichment platform with several operating facilities in South Africa, and a divisional structure that spreads risk.
- PET Labs shows strong organic growth and an expanding radiopharmaceutical product flow.
- Renergen brings helium and LNG production capacity, and long-term contracts under discussion could provide revenue visibility.
Weaknesses
- The company had not generated revenue from sales of enriched isotopes as of June 30, 2026, and net losses continue.
- Reliance on a few large customers could make revenue vulnerable to delays or the loss of a single contract.
- The company has identified a material weakness in internal control over financial reporting, and its capital needs are substantial.
Opportunities
- A separate listing of QLE and a possible distribution of its shares to shareholders could clarify the value of each division.
- Demand for helium from geopolitically neutral sources could support Renergen revenue if Phase 1 is completed on schedule.
- Development of new isotopes and expansion in radiopharmaceuticals could open new revenue lines in coming years.
Threats
- Technical delays with equipment and political or economic instability in South Africa could affect project execution.
- Export controls and rules on dual-use technology could restrict operations and commercialization.
- Volatility in natural gas and helium prices could reduce Renergen profitability.
Risks
- Continuing losses and need for capitalhigh
The company reported a net loss of 159.8 million USD in fiscal 2025 and expects significant losses to continue, which could make it necessary to raise capital on unfavorable terms 1.
- Export controls and dual-use statusmedium
Enrichment technologies could be classified as dual-use, which could limit their publication and export.
- Operational risk in South Africamedium
Economic, political or social instability could disrupt project development and operations.
- Dependence on a few large customersmedium
Revenue could depend on a small number of customers, and losing one could materially affect results.
Investment thesis
What would need to be true (bull case)
- If PET Labs and Renergen reach their revenue and EBITDA targets, the company could reduce its dependence on isotopes not yet proven commercially.
- Demand for helium from alternative sources could provide long-term revenue if take-or-pay contracts materialize.
- A separate listing of QLE could highlight the value of the nuclear fuels division if the market responds favorably.
What would break the thesis
- Repeated losses and the need for additional funding could dilute shareholders if expected milestones do not materialize.
- If isotope production stays delayed, expected revenue could remain below expectations for a long period.
- A complex structure with many subsidiaries and intra-group transactions could make it hard to value the company accurately.
What to watch
- Start of helium production at Renergen and completion of Phase 1before September 30, 2026
- PET Labs results and achievement of its 2026 revenue target2026
- QLE listing timing and distribution of shares to shareholdersnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
ASP Isotopes operates through subsidiaries and focuses on its proprietary ASP and QE enrichment technologies, with its first isotope products targeted for commercial shipments in 2026. The company is active in three directions: specialist isotopes, nuclear fuels through the subsidiary Quantum Leap Energy and, since 2026, natural gas and helium through Renergen. Fiscal 2025 brought a net loss of 159.8 million USD, and cumulative losses bring the accumulated deficit to 231.3 million USD 1.
Segments
Nuclear fuels (Quantum Leap Energy)
The QLE subsidiary pursues advanced nuclear fuels such as HALEU and lithium-6, with a uranium enrichment project in South Africa. The company intends to list QLE separately on a US exchange, and QLE confidentially submitted a draft Form S-1 in November 2025 1.
Natural gas and helium (Renergen)
Renergen, acquired in January 2026, produces LNG and liquid helium from the Virginia Gas Project. The company estimates annualized helium and LNG revenue of about 27 million USD after Phase 1 is completed, though these estimates depend on project execution 3.
Market context
The isotope market divides into niches in medicine, semiconductors and nuclear energy, each with different product cycles. According to the shareholder letter, about half of global helium supply is currently estimated to be offline, which could create demand for a supplier in a geopolitically neutral location 3. Demand for therapeutic radioisotopes could grow as more drugs are approved, but this remains uncertain.
Trends
- Demand for alternative helium supplytailwind
A global helium shortfall could support pricing and customer interest in new suppliers if the supply situation does not normalize.
- Nuclear regulation and export controlsheadwind
Enrichment technologies may be treated as dual-use, which could limit their publication or export.
- Growing demand for radiopharmaceuticalstailwind
The large number of radiotherapy drugs in clinical trials could create need for more radioisotopes, particularly for PET Labs operations.
Competitive position
The supplied sources do not name direct competitors for ASP Isotopes. The company only notes that QLE could face competition from existing or new companies, which could create downward pressure on prices and market share. The sources do not provide information on the company's relative position against other suppliers.
- Existing and new entrants in nuclear enrichment
Mentioned in the QLE risk factors as a possible source of price and market share pressure, without named companies in the sources.
- Existing helium suppliers
The shareholder letter indicates a partly offline global helium supply but does not name specific competitors.
- Radiopharmaceutical producers
PET Labs operates in a radiopharmaceutical market where competitors are not identified in the supplied sources.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report26 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report15 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report02 Oct 2026Regulation FD disclosure
- Current report08 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report20 Aug 2026Material agreement · Termination of a material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report20 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Current report18 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report06 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Current report05 Aug 2026Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / ASP Isotopes Inc. · 10 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / ASP Isotopes Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / ASP Isotopes Inc. · 04 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.